Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
557.00    3.00 (0.54%)
Bid:
557.50
Ask:
558.00
Spread: 0.50 (0.09%)
Market Cap: £2.47b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Tate & Lyle Capital Markets Event

1 Jul 2025 07:00

RNS Number : 0295P
Tate & Lyle PLC
01 July 2025
 

1 July 2025 - Tate & Lyle PLC

 

Tate & Lyle Capital Markets Event

 

Tate & Lyle PLC (Tate & Lyle) is today hosting a Capital Markets event for investors and analysts in central London.

 

The event will cover Tate & Lyle's strategy, portfolio, markets and financial framework, and our focus on accelerating top-line growth. The event includes presentations on:

 

· The CP Kelco business and the power of the combination with Tate & Lyle.

· The growth opportunity for our solutions from addressing key societal trends.

· How our expanded Mouthfeel portfolio and capabilities is strengthening our ability to provide customers with reformulation solutions.

· How our expanded scientific and innovation capabilities, and investment in new technologies, are placing us at the centre of the future of food.

 

The event will be hosted by Nick Hampton, Chief Executive, Sarah Kuijlaars, Chief Financial Officer, and other members of the Tate & Lyle senior management team. 

 

Following the Group's recent full-year results' announcement on 22 May 2025, no new material trading information or updates in respect of the current financial year ending 31 March 2026 will be provided during the event.

 

Nick Hampton, Chief Executive said:

"Over the last seven years, we have re-positioned Tate & Lyle to be right at the centre of the future of food, with the portfolio and capabilities to meet customers, consumers and society's growing demand for healthier, more nutritious and sustainable food and drink. A global leader in sweetening, mouthfeel and fortification, Tate & Lyle is a scale, speciality solutions business with a clear focus on accelerating top-line growth.

 

At today's event we look forward to outlining the large and attractive markets we operate in, showcasing our expanded portfolio and capabilities, and to demonstrate the power of the CP Kelco combination and how it is broadening our solutions offering for customers."

 

Event details

The event will start at 13.30 BST and is expected to last around 3 hours including Q&A. To join the event live online, including the above presentations and Q&A, please register here.  The slides to be presented at the event will also be available from the investor relations section of our website shortly before the event.

 

A replay of the recorded webcast will be available shortly after the event here.

 

Visit to production facility in Denmark on 3 July 2025

Investors and analysts will also be participating in a site visit to Tate & Lyle's pectin facility and labs in Lille Skensved, near Copenhagen, Denmark on Thursday 3 July 2025. This visit will include an overview of the scientific and production process for pectin and carrageenan, a plant tour, and an R&D demonstration and prototype tasting experience.

 

END

For more information contact Tate & Lyle PLC:

 

Christopher Marsh, VP Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Nick Hasell, FTI Consulting (Media)

Tel: Mobile: +44 (0) 7825 523 383

Tel: Office: +44 (0) 203 727 1340

tate@fticonsulting.com

 

 

About Tate & Lyle PLC:

Supported by our 165-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients and solutions every day.

 

Through our leading expertise in sweetening, mouthfeel and fortication, we develop ingredients and solutions which reduce sugar, calories and fat, add bre and protein, and provide texture and stability to food and drink in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

 

Tate & Lyle recently acquired CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients to create a leader in mouthfeel, significantly enhancing our solutions capabilities. Following this combination, we now have more than 5,000 employees working in around 75 locations in 38 countries, serving customers in more than 120 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives through the Science of Food. By living our purpose, we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. For the year ended 31 March 2025, and on a pro forma basis which assumes for illustrative purposes that the combination with CP Kelco took place on 1 April 2024, revenue for the enlarged Tate & Lyle Group would have been £2.12 billion. For more information, please visit www.tateandlyle.com or follow Tate & Lyle on LinkedInX (Twitter)Facebook or YouTube

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCWPUMPQUPAGWU
Date   Source Headline
1st Jul 20263:25 pmRNSForm 8.3 TATE & LYLE PLC
1st Jul 20263:18 pmRNSForm 8.3 TATE & LYLE PLC
1st Jul 20263:14 pmRNSForm 8.3 - Tate & Lyle PLC
1st Jul 20263:12 pmRNSForm 8.3 - Tate & Lyle plc
1st Jul 20263:06 pmRNSForm 8.3 - Tate & Lyle plc
1st Jul 20262:32 pmRNSDirector/PDMR Shareholding
1st Jul 20262:27 pmRNSForm 8.3 - Tate & Lyle plc
1st Jul 20262:17 pmRNSForm 8.3 - Tate & Lyle plc
1st Jul 20262:13 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
1st Jul 20262:05 pmRNSForm 8.3 Tate & Lyle plc
1st Jul 20261:58 pmRNSForm 8.3 Tate & Lyle PLC
1st Jul 202612:33 pmRNSForm 8.3 - Tate & Lyle plc
1st Jul 202611:42 amRNSForm 8.5 (EPT/RI)-TATE & LYLE PLC
1st Jul 202611:39 amRNSForm 8.5 (EPT/NON-RI) - Tate & Lyle plc
1st Jul 202611:33 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
1st Jul 202611:26 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
1st Jul 202611:10 amRNS20260630_TATE & LYLE_8.5 EPT RI_UK_MLI
1st Jul 202610:40 amRNSForm 8.3 Tate & Lyle Plc
1st Jul 20269:08 amRNSForm 8.5 (EPT/RI) - Tate & Lyle PLC
30th Jun 20263:29 pmRNSForm 8.3 TATE & LYLE PLC
30th Jun 20263:25 pmRNSForm 8.3 TATE & LYLE PLC
30th Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
30th Jun 20263:01 pmPRNInvesco Ltd: Form 8.3 - Tate & Lyle PLC; Public dealing disclosure
30th Jun 20263:00 pmRNSForm 8.3 - Tate & Lyle plc
30th Jun 20262:48 pmRNSForm 8.3 - Tate & Lyle plc
30th Jun 202612:54 pmRNSForm 8.3 - Tate & Lyle plc
30th Jun 202612:35 pmRNSForm 8.3 - Tate & Lyle plc
30th Jun 202612:34 pmRNSForm 8.3 Tate & Lyle Plc
30th Jun 202611:50 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
30th Jun 202611:45 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
30th Jun 202611:39 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
30th Jun 202611:13 amRNS20260629_TATE & LYLE_8.5 EPT RI_UK_MLI
30th Jun 202610:40 amRNSForm 8.3 - Tate & Lyle plc
30th Jun 202610:34 amRNSForm 8.5 (EPT/RI)-TATE & LYLE PLC
30th Jun 202610:05 amRNSForm 8.3 Tate & Lyle plc
30th Jun 20269:14 amRNSForm 8.5 (EPT/RI)
30th Jun 20267:00 amRNSForm 8.5 (EPT/RI)- Tate & Lyle plc Amend
30th Jun 20267:00 amRNSForm 8.5 (EPT/RI)- Tate & Lyle plc Amend
29th Jun 20263:25 pmRNSForm 8.3 TATE & LYLE PLC
29th Jun 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
29th Jun 20262:35 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
29th Jun 20262:08 pmRNSForm 8.3 - Tate & Lyle plc
29th Jun 20261:58 pmRNSForm 8.3 Tate & Lyle Plc
29th Jun 20261:03 pmRNSForm 8.3 Tate & Lyle Plc
29th Jun 202612:40 pmRNSForm 8.3 - Tate & Lyle plc
29th Jun 202611:21 amRNS20260626_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
29th Jun 202611:19 amRNS20260626_TATE & LYLE_8.5 EPT RI_UK_MLI
29th Jun 202611:18 amRNSForm 8.3 - Tate & Lyle Plc
29th Jun 202611:17 amRNSForm 8.5 (EPT/NON-RI) - TATE LYLE PLC
29th Jun 202611:13 amRNSForm 8.5 (EPT/NON-RI) - Tate & Lyle plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.